- Home
- CCBG vs EYPT Comparison
CCBG vs EYPT Comparison
Compare CCBG & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CCBG | EYPT |
|---|---|---|
| Founded | 1895 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 874.1M | 419.9M |
| IPO Year | 1994 | 2005 |
Fundamental Metrics
Financial Performance| Metric | CCBG | EYPT |
|---|---|---|
| Price | $49.47 | $4.02 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $50.00 | $31.80 |
| AVG Volume (30 Days) | 51.2K | ★ 4.0M |
| Earning Date | 04-20-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.34% | N/A |
| EPS Growth | ★ 15.38 | N/A |
| EPS | ★ 0.92 | N/A |
| Revenue | N/A | ★ $7,539,000.00 |
| Revenue This Year | $6.25 | N/A |
| Revenue Next Year | $3.17 | $3,115.57 |
| P/E Ratio | $54.55 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $38.27 | $3.42 |
| 52 Week High | $53.60 | $19.11 |
Technical Indicators
Market Signals| Indicator | CCBG | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 38.69 | 31.71 |
| Support Level | $49.74 | $3.95 |
| Resistance Level | $51.57 | $14.72 |
| Average True Range (ATR) | 0.99 | 0.32 |
| MACD | -0.13 | 0.22 |
| Stochastic Oscillator | 23.10 | 37.33 |
Price Performance
Historical ComparisonAbout CCBG Capital City Bank Group
Capital City Bank Group Inc is a United States-based group engaged in Banking services, Trust and asset management services, and Brokerage services. The company operates in one segment with two principal services: Banking Services and Wealth Management Services. It offers retail and commercial banking business in the form of traditional deposit and credit services, asset management, trust, mortgage banking, merchant services, bank cards, data processing, and securities brokerage services, among others, through its banking offices in Florida, Georgia, and Alabama.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.